MedTrace Logo

F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies

NCT03456908 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2020-09-16

No results posted yet for this study

Summary

The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. .

Conditions

  • Myeloma Before MV-NIS Treatment
  • Endometrial Cancer Before VSV-hINF-NIS Treatment

Interventions

COMBINATION_PRODUCT

18F-TFB-PET

Infusion of F-18 TFB and PET / CT imaging

Sponsors & Collaborators

Principal Investigators

  • Timothy R DeGrado, PhD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-16
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03456908 on ClinicalTrials.gov